Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

BeiGene Acquires Asia Rights to Mirati Cancer Treatment in $133 Million Deal

publication date: Jan 15, 2018

BeiGene, a Beijing cancer company, in-licensed Asian rights to a clinical-stage lung cancer therapy from Mirati Therapeutics of San Diego. Sitravatinib is a spectrum-selective kinase inhibitor that has shown clinical efficacy in a Phase II trial in combination with a PD-1 checkpoint inhibitor. BeiGene, which will test sitravatinib in conjunction with its own PD-1 candidate, will pay $10 million upfront and up to $123 million in milestones. More details....

Stock Symbols: (NSDQ: BGNE) (NSDQ: MRTX)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.